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Abstract
The development of safe topical microbicides that effectively prevent human immunodeficiency
virus (HIV) infection is a major goal in curbing the human immunodeficiency virus pandemic. A
number of past failures resulting from mucosal toxicity or lack of efficacy have informed the field.
Products that caused toxicity to the female genital tract mucosa, and thereby increased the
likelihood of HIV acquisition, included nonoxynol 9, cellulose sulfate, and C31 G vaginal gel
Savvy®. Topical products that were ineffective in preventing HIV infection include BufferGel®,
Carraguard®, and PRO 2000®. Antiretroviral drugs such as tenofovir and dapivirine formulated
into microbicide products have shown promise, but there is much to learn about ideal product
formulation and acceptability, and drug distribution and disposition (pharmacokinetics). Current
formulations for water-soluble molecules include vaginally or rectally applied gels, vaginal rings,
films and tablets. Dosing strategies (e.g. coitally dependent or independent) will be based on the
pharmacokinetics of the active ingredient and the tolerance for less than perfect adherence.
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Introduction
In order to be effective, an ideal microbicide should not cause mucosal irritation, should
distribute into the tissues that are associated with HIV transmission, be metabolised
efficiently to their active components (if necessary), and achieve adequate and sustained
concentrations for protection against human immunodeficiency virus (HIV) transmission.
Absorption into the systemic circulation, and subsequent exposure in blood plasma, should
be minimal to diminish systemic adverse effects and the potential for the virus to become
drug resistant if HIV infection should occur. A microbicide must also be easy to use and
well accepted by the target population. In this chapter, we discuss the lessons learned from
past microbicide failures, review successes and outline current knowledge of microbicide
formulations in development.
© 2012 Elsevier Ltd. All rights reserved.
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Microbicide vehicles are important, as they allow the active drug to reach the proper site of
activity, to distribute throughout the luminal surface (vagina or colorectum), and remain at
the surfaces for an adequate (as yet undefined) period of time. Vehicles can include aqueous
gels, reservoir rings, and locally applied solid films and tablets.
Physiochemical characteristics of a gel vehicle that must be optimised include volume,
viscosity, yield stress, sheer rate, pH and osmolality.1 Reservoir rings must be formulated to
provide long-term, predictable, sustained release of an active component throughout the
vaginal compartment.2 Film polymers should be non-toxic, non-irritant, have adequate
wetting, spreadability, disintegration over time, and strength. Solid vaginal tablets must also
have adequate disintegration and dispersion throughout the vaginal compartment without
causing irritation.1 For all formulations, it is important that the pharmaceutically active
compound be stable in the vehicle in which it is formulated, and uniformly distributed to
allow for broad distribution in the vaginal compartment. A full list of the advantages and
disadvantage of each of the formulations in development is presented in Table 1.
Toxicity to vaginal mucosa
Above all, the field has learned that microbicides must demonstrate no mucosal toxicity,
which can lead to irritation, epithelial disruption, release of cytokines, immune activation
and changes to flora, which increase the risk of HIV acquisition. In order for a product to be
compatible with the mucosal environment, physiologic pH must be maintained and the
product should be iso-osmolar.3 Past microbicide gel failures owing to local mucosal
toxicity included those containing nonoxynol 9,4 cellulose sulfate,5 and Savvy®.6 The
following is a summary of the findings from those studies.
Nonoxynol-9
COL-1492 was a phase III, randomised, placebo-controlled study in 765 female sex workers
using 1.5 g of carbomer gel (a polymer with bio-adhesive properties), containing 3.5%
nonoxynol-9 (a spermicidal surfactant).4 A 16% seroconversion rate was seen in the active
arm of the study, compared with 12% in the placebo arm. Women who used the product
more frequently had higher rates of HIV infection and were found more likely to have
lesions with epithelial disruption. Those women reporting a mean applicator use greater than
3.5 per working day had a hazard ratio of 1.8 (1.0 to 3.2) for HIV incidence (P = 0.03)
compared with placebo. Subsequently, it was determined that nonoxynol-9 causes cytokine
release, immune-cell recruitment, and alterations in vaginal flora, all of which may make
women more susceptible to HIV acquisition.7 In particular, release of the cytokine
interleukin-1 activates nuclear factor-kappa B, leading to chemokine-induced immune cell
recruitment, which provided host cells for HIV-1 infection and increased HIV replication.8
In another study,9 after the use of nonoxynol-9 containing diaphragms, women had vaginal
colonisation of Escherichia coli, Enterococcus species, and anaerobic gram-negative rods,
which could also lead to immune activation and immune-cell recruitment.
Cellulose sulfate
Cellulose sulfate is a polyanion entry inhibitor with in-vitro activity against HIV-1 and
HIV-2, as well as Neisseria gonorrhoeae, and Chlamydia trachomatis.10 It was found to be
well tolerated in early phase safety studies using single and multiple daily doses for up to 2
weeks.11–14 A phase III study compared 3.5 ml of 6% cellulose sulfate gel with placebo gel
in 1398 women 1 h before intercourse. Interim analysis found 24 seroconversions in the
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cellulose sulfate arm and 11 in the placebo arm (hazard ratio 2.23; P = 0.02) leading to
premature discontinuation of the study. Final analysis revealed 25 out of 706
seroconversions in the cellulose sulfate arm and 16 out of 692 in the placebo arm (hazard
ratio 1.61; P = 0.13).5 Possible explanations of the results include increased inflammatory
reactions and immune cell recruitment.15 Although not statistically significant, one of the
safety studies had shown slightly more women with signs of increased inflammation on
colposcopy after using cellulose sulfate gel twice daily for 14 days.16
SAVVY®
The chemical compound C31 G (SAVVY®) is a surfactant that disrupts the outer membrane
of HIV with a similar mechanism to nonoxynol-9.17 In multiple phase I studies, signs of
irritation with repeat dosing of 1% SAVVY® were reported, but considered less toxic than
nonoxynol 9.18–20 One colposcopy study found 1.2% SAVVY® to cause similar epithelial
disruption as 2% nonoxynol-9.21 Subsequently, a phase III study6 enrolling 2153 women
using 3.5 ml of product in a coitally dependent manner observed more seroconversions in
the active arm (21 out of 1076) than in the placebo arm (12 out of 1077). The study was
stopped early because of an overall lower than expected HIV incidence: mid-point analysis
determined that an additional 1980 participants would be needed to reach the overall 66
events required to show efficacy. The true hazard ratio and reasons for the increased number
of infections in the SAVVY® arm could not be determined. An additional parallel phase III
study of 2142 women in Ghana was also stopped early because of a lower than expected
HIV incidence rate.22
Vivagel®
Vaginal irritation and inflammation was found to occur when 3% Vivagel® (SPL 7013) was
used twice daily for 14 days. Two out of 35 women discontinued the gel as a result of
genital irritation, confirmed on colposcopy.23 A second study of 3% Vivagel®24 evaluated
inflammatory markers in the vaginal mucosa of women using the gel twice daily for 14
days. By day 7, interleukin-6, CD8+ and CD69+ cells, CD4+ and CD69+ cells and CD4+
and CCR5+ cells were all elevated (P < 0.05) in women using the gel compared with
placebo. By day 14, interferon gamma, interleukin-5 and interleukin-10 (P = 0.001) were
elevated. All were reversible with discontinuation of VivaGel®, and this product is
continuing in Phase II studies for the treatment and prevention of bacterial vaginosis.25
Lack of efficacy
A number of topical microbicides have failed to show efficacy at preventing HIV infection,
including BufferGel®,26 PRO 2000®,27 and Carraguard®.28 By maintaining vaginal pH 4.0–
4.5 in the presence of semen, BufferGel® was intended to protect against HIV infection by
broadly acidifying pathogens.29 A phase II/IIb, four-arm study in 3101 women comparing
BufferGel® with 0.5% PRO 2000® gel, placebo gel, and no gel found no difference in HIV
infection rates between BufferGel® and placebo gel (hazard ratio 1.10; P = 0.63), and
BufferGel® and no gel (hazard ratio 1.05, P = 0.78).26 This same study showed modest
benefit of a 0.5% PRO 2000® gel over placebo gel (hazard ratio 0.7, P = 0.10) and no gel
(hazard ratio 0.67, P = 0.06).26
PRO 2000® gel is a synthetic naphthalene sulfonate polymer that inhibits viral attachment
and entry. It demonstrated antiviral activity in macaques30 and in vitro.31 A subsequent
phase III study27 showed that 2% and 0.5% of PRO 2000® gel were ineffective at
preventing HIV infection compared with placebo. The 2% PRO 2000® gel arm was stopped
prematurely due to futility, and the 0.5% PRO 2000® gel arm failed to show a difference in
HIV incidence compared with placebo (hazard ratio 1.05; P = 0.71).
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Carraguard® contains the polyanion carrageenan. The mechanism is not fully understood,
but it may bind the positively charged regions of the viral envelope and act as a barrier to
host cells. It was previously shown to prevent effectively HIV infection in vitro32 and in
macaques.33 In a phase III study conducted in 6005 women in South Africa, 4 ml of 3%
Carraguard® failed to demonstrate efficacy compared with placebo (covariate adjusted
hazard ratio 0.87, 95% CI 0.69 to 1.09).28
Owing to the significant number of failures of surfactants, polyanions, and general
antimicrobials, a number of small molecule antiretroviral drugs are under investigation. A
review of the microbicide formulations that are currently under development follows. A
summary of these data are presented in Table 2.
Microbicide gels
Antiretroviral drugs formulated as gels show promise in preventing HIV infection. Gel
formulations allow for the application of antiretroviral drugs directly to the vaginal mucosa
with limited systemic absorption and side-effects, and HIV resistance potential. Currently,
tenofovir with and without emtricitabine, and dapivirine are being investigated in gel
formulations.
Tenofovir
Tenofovir is a nucleotide reverse transcriptase inhibitor used orally in combination for the
treatment of HIV-1.34 It acts as a nucleoside analogue that terminates HIV transcription
from RNA to DNA before integration into the host cell genome.34 By targeting a place in
the HIV life cycle before genome integration, tenofovir could theoretically prevent initial
cellular infection. Tenofovir gel has been tested in macaques, humanised mice, and in
clinical studies.
Tenofovir 1% gel has been tested in macaques, with repeated exposure to the chimeric
simian-human immunodeficiency virus (SHIV). In one study, 3 ml tenofovir 1% gel given
vaginally to female macaques twice weekly before SHIV challenge for a total of 20
challenges protected six out of six macaques from infection.35 Additionally, tenofovir 1%
gel protected four out of six macaques against SHIV challenge 3 days after gel
application.36 Rectally applied 1% tenofovir gel was shown to protect eight out of nine
macaques when applied 2 h before simian immunodeficiency virus exposure.37
Pharmacokinetic data of both vaginal and rectally applied 1% tenofovir gel in macaques
showed quick and thorough distribution throughout mucosal surfaces, with concentrations
4–5 logs higher in the mucosal compartment than in blood plasma.38
In humanised mice, topically applied tenofovir 1% gel was found to be 88% effective (P =
0.002) at preventing HIV infection compared with placebo gel when 20 μl of gel was
applied vaginally 4 h before and after HIV challenge.39
A phase I pharmacokinetic study in humans assessed 2 weeks of single and multiple dosing
of once or twice daily 4 ml applications of 1% tenofovir vaginal gel in blood plasma,
endocervical cells, cervicovaginal fluid aspirates, and vaginal tissue in 49 women from the
Dominican Republic and two US sites.40 Tenofovir achieved high persistent concentrations
within the vaginal lumen and tissues, and minimal concentrations in the systemic
circulation. No differences between proximal and distal tissue concentrations were found,
demonstrating uniform distribution throughout the vagina. Cervicovaginal fluid
concentrations were greater than 1,000,000 ng/ml within the first 4 h of dosing, and fell to
100,000 ng/ml by 24 h. Tenofovir vaginal tissue concentrations were found to be
approximately one to two logs (10 to 100 times) lower than luminal concentrations. About
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3–5% of the tenofovir was metabolised intracellularly to the active metabolite tenofovir
diphosphate, in vaginal and cervical cells within 30 mins of dosing. Blood plasma
concentrations after vaginal application were less than 5% of those previously reported after
oral dosing.41 These data were subsequently confirmed in an additional study using an
African population.42
The vaginally formulated 1% tenofovir gel was assessed in a phase I placebo-controlled
crossover study investigating rectal administration compared with oral administration of
tenofovir disoproxyl fumarate.43 Eighteen healthy adults sequentially received a single dose
of oral tenofovir disoproxyl fumarate 300 mg, then either 1% tenofovir gel applied rectally
or a placebo gel. Rectal dosing resulted in 30-fold lower plasma exposure than oral dosing.
Ex-vivo HIV challenges were carried out on rectal biopsies obtained after 7 days of daily
rectal gel use. Concentrations of the active form of the drug, intracellular tenofovir
diphosphate, greater than 1000 fmol/mg were required to see significant suppression of viral
replication in these tissues. As significant gastrointestinal discomfort was seen with the
vaginal formulation of this gel, a rectal-specific gel with decreased osmolality has been
formulated and is undergoing clinical safety and efficacy studies.44,45
Tenofovir 1% gel was the first antiretroviral to demonstrate its ability to prevent the sexual
transmission of HIV.46 In the CAPRISA 004 study conducted in rural and urban sites in
South Africa,47 843 women were instructed to vaginally apply 4 ml of 1% tenofovir gel up
to 12 h before and after sex with no more than two doses used in 24 h. This method was
proven to be 39% effective at preventing HIV infection compared with placebo overall. In
women with over 80% adherence (as assessed by used applicator counts), efficacy was 54%.
Pharmacological analysis of cervicovaginal fluid samples found a direct correlation between
higher tenofovir concentrations and protection from both HIV infection and herpes simplex
2 infection (a surprising and unexpected benefit). Kaplan–Meier analysis showed that
women with cervicovaginal fluid concentrations of tenofovir less than 1000 ng/ml had an
HIV incidence rate similar to that of women using placebo. Women with cervicovaginal
fluid concentrations greater than 1000 ng/ml had a significantly lower chance of acquiring
HIV.48
The VOICE (Vaginal plus Oral Interventions to Control the Epidemic; MTN 003) study49
was designed to compare the efficacy of daily dosed 1% vaginal gel, a placebo gel, oral
tenofovir, oral tenofovir plus emtricitabine and an oral placebo. In November 2011, the daily
1% tenofovir gel arm of the study was halted due to futility. With about 1000 women
enrolled in each arm, a review of the data from September 9, 2011 to September 30, 2011
found a 6.1% infection rate in the placebo gel arm and a 6.0% infection rate in the tenofovir
gel arm. The reasons for the failure of this VOICE arm after the 39% success rate of
CAPRISA 004 have yet to be determined. Limited adherence to the daily dosing of tenofovir
1% gel or increased drug exposures with the CAPRISA 004 strategy may have been factors.
One additional phase III study of 1% tenofovir vaginal gel called FACTS 001 (Follow-on
African Consortium for Tenofovir Studies) is currently ongoing. FACTS 001 is evaluating
the effectiveness of the CAPRISA 004 dosing strategy in 2200 women in South Africa.50
Dapivirine
Because of its poor oral bioavailability, dapivirine (TMC120) is being developed solely as a
topical non-nucleoside reverse transcriptase inhibitor for the prevention of HIV infection.
Dapivirine allosterically blocks the reverse transcriptase enzyme and thereby prevents the
complete transcription of HIV RNA to DNA.51 Dapivirine’s tight binding to reverse
transcriptase and high lipophilicity makes it active against both cell associated and cell free
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virus in semen without the metabolic activation that is needed for nucleotide reverse
transcriptase inhibitors.52
In animal studies, a 0.009% dapivirine vaginal gel was given over 7 days to both rabbits (0.5
ml per day) and macaques (1 ml per day). Pharmacokinetic data in both species showed low
plasma drug concentrations (maximum 0.225 ng/ml). Cervical and vaginal tissue
concentrations were above the in-vitro 90% Effective Concentration (EC90) of 0.9 ng/ml for
up to 48 h after dosing. Microautoradiography identified drug-related material on the
surfaces of vaginal and cervical tissues, suggesting that the drug may reside in compromised
areas of tissues and provide a protective effect at vulnerable lesions and ulcers.53,54
Dapivirine has shown to be safe and well tolerated with low systemic absorption in phase I
and II studies investigating 2.5 ml doses of 0.001, 0.002, 0.005, and 0.02% dapivirine
vaginal gel given twice daily for 42 days to 119 women. Plasma concentrations were dose
proportional over the range studied, with no accumulation past 7 days of dosing. The
maximum observed plasma concentration was a low 474 pg/ml in the 0.02% dose group.55
Dapivirine concentrations in cervicovaginal fluids and tissues were found to be well
distributed throughout the vaginal compartment over 10 days of gel dosing in 18 healthy
women. Women applied 2.5 ml of either 0.001%, 0.005% or 0.02% dapivirine gel once
daily on days 1 and 10 and twice daily on days 2 to 9. Fluid concentrations were found to be
4.6–8.3 × 106 pg/ml on day 1 and 2.3–20.7 × 106 pg/ml on day 10, and cervicovaginal tissue
biopsies collected on day 10 had concentrations of 1.0–356 × 103 pg/mg.56
Recently, a phase I study57 evaluated two different formulations of 0.05% dapivirine gel for
pharmacokinetics and safety. The gels were applied daily for 11 days, and both were safe
and well tolerated. The maximal dapivirine plasma concentrations did not exceed 1.1 ng/ml.
The cervicovaginal fluid concentrations were 5 logs higher than dapivirine’s in-vitro IC50
for wild type HIV-1 virus and 3 to 5 logs higher than the in-vitro IC50 for virus containing
the non-nucleoside reverse transcriptase inhibitor resistance mutation Y181C. The terminal
half-life was 16–17 h. The dapivirine gel is currently undergoing additional phase I and II
studies.58
Combination gel products
Combinations of drugs formulated into a gel have a number of theoretical advantages.
Combining drugs with different resistance profiles may protect against transmission of a
virus with mutations to one of the agents, and may protect against rapid development of
resistance if infection occurs.1 Additionally, combining drugs that act synergistically or
additively may allow for lower doses of agents used in combination than used individually,
thereby minimising systemic exposure and adverse effects.
Combinations currently under investigation include tenofovir with emtricitabine, and
tenofovir with dapivirine.58 Macaques given 3 ml of gel combining 1% tenofovir with 5%
emtricitabine were all protected against SHIV infection. Only 0.03% of the tenofovir dose
and 0.025% of the emtricitabine dose were systemically absorbed 30 mins after gel
application.35
In-vitro data suggest that dapivirine combined with tenofovir may be synergistic against
transmitted viruses containing a particular non-nucleoside reverse transcriptase inhibitor
mutation (Y181C). This virus is easily transmitted because it confers little or no fitness
cost.59 This study supports the hypothesis that combination microbicide products may retain
antiviral activity against resistant viruses, thereby better protecting against the transmission
of resistant viruses.60
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Vaginal rings containing antiretroviral drugs are similar in concept to vaginal rings currently
used for contraception and hormone replacement therapy.2 The intention of the ring is to
maintain long-term, sustained antiretroviral release for local effect. Owing to the long-term
drug release, rings can be used in a coitally independent manner, and only inserted monthly.
This may have an adherence benefit over other microbicides in development.
Dapivirine
Dapivirine has been formulated into a ring currently undergoing phase III studies.58
Previously, two phase I studies evaluated dapivirine 25 mg and 200 mg delivered from a
vaginal ring over 7 days in 25 healthy women. Both studies found the ring to be safe, and
adverse effects similar to placebo. Mucosal fluid was sampled at 4 h, 24 h and 7 days after
insertion in all women from the introitus, cervix and ring area, and mean drug
concentrations exceeded 1000 times the EC50 against wild-type HIV-1. In both studies, the
mean concentrations of dapivirine were 0.7 to 7.1 μg/ml in mucosal fluid, and ranged from
0.3 to 3.5 μg/g in cervical and vaginal tissues. The authors point out that the lowest
concentration in any of the tissues sampled was over 30-fold higher than the in-vitro EC90.
Plasma concentrations did not exceed 40 pg/ml with this device.61
A recent double-blind, randomised (3:1) placebo-controlled study in 48 women62 evaluated
the pharmacokinetics of multiple dosing of a 25 mg dapivirine vaginal ring. Dapivirine
concentrations and safety assessments were measured over a total of 88 days. Dapivirine
concentrations peaked in vaginal fluid within the first 24 h after the ring was inserted.
Concentrations above 0.3 ng/ml (IC50) were maintained up to 35 days. Minimum
concentrations were 1.9, 1.4 and 0.7 μg/g measured near the ring, at the cervix and the
introitus, respectively; maximum concentrations were 66.1, 58.4 and 40.1 μg/g. Maximal
plasma concentrations were 553 pg/ml. This study verified both the safety of the dapivirine
ring and the ability of this product to maintain consistent drug delivery over 35 days.
Combination rings
A combination dapivirine and maraviroc ring is currently in phase 1.63 These two
antiretroviral drugs work differently: dapivirine by allosterically inhibiting reverse
transcriptase, and maraviroc by preventing HIV from binding to the cell surface co-receptor
CCR5.64 A dapivirine plus maraviroc combination gel has also been formulated, but studies
of the gel are on hold to focus on the development of the ring formulation.65 Additionally,
combining antiretroviral drugs with contraceptives into a single vaginal ring may be
beneficial for women who seek protection against HIV infection while also avoiding
conception. One of the largest challenges to the development of a dual releasing vaginal ring
is creating differing dissolution conditions for drug entities with disparate physicochemical
properties.66
Microbicide films and tablets
Intravaginal films and tablets are already used as antifungals, antibacterials, and hormone
replacement products. Advantages of these dosage forms include their portability, ease of
storage and ease of use. Additionally, solid dosage forms can stabilise drugs that would be
otherwise degraded in an aqueous solution. Limitations include an increased risk of vaginal
irritation and the need for vaginal hydration to assure uniform distribution and tissue
absorption.1
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The retrocyclin 1 peptide analog, RC-101, is currently being studied in a vaginal film
formulation. This entry inhibitor prevents the binding of HIV to both CXCR4 and CCR5 co-
receptors located on CD4+ cells in vitro.67 RC-101 is best formulated in a non-aqueous solid
film dosage form because the peptide is degraded in semisolid aqueous solutions.68,69
RC-101 was formulated into a quick-dissolving 2000 μg per film product and applied
intravaginally to six female macaques daily for 4 days. Over this time, the peptide was
detected in cytobrush and tissue samples, but not in cervicovaginal lavage or plasma.
Cervical and vaginal tissues taken from two macaques one day after the last film application
were protected from SHIV challenge in an ex-vivo culture system. Colposcopy revealed no
mucosal changes. This study contributes to the continued development of RC-101 vaginal
film.68
Other films and tablets are in early preclinical development, and include a film containing a
combination of tenofovir with maraviroc,58 and a vaginal tablet containing BMS793, a
gp120 mediated cell attachment inhibitor.58
Conclusion
A major advantage to the development and use of locally applied microbicides to prevent
HIV infection is the ability to preclude partner negotiation, as must occur with condoms.
Various topical formulations are being developed to provide a variety of options for a safe,
effective, and acceptable product that can protect against HIV infection. Regardless of
potency, microbicides will only be effective if they are used properly and consistently.70 A
successful product rests on the ability to safely achieve adequate concentrations to prevent
HIV transmission in mucosal tissues, and to maintain those concentrations throughout the
window of most risk for HIV acquisition. As shown by CAPRISA 004 and VOICE, the most
appropriate dosing regimen to ensure adherence, while also maintaining adequate
microbicide concentrations, is yet to be determined. Just as they have for treatment,
combination regimens that target different steps in the HIV life-cycle may prove most
effective for prevention.
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• An optimal microbicide formulation must be discrete, easy to use, safe for
mucosal tissues, stable under a variety of climate conditions, and distribute
evenly.
• Product acceptability is critical for optimal adherence because no HIV
prevention method will be effective if the target population does not find it easy
to use.
• Drug concentrations protective of HIV infection in mucosal tissues have yet to
be determined; the pharmacokinetics and drug exposure will dictate optimal
dosing regimens.
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• Pharmacokinetic exploration of differing results between CAPRISA 004 and
VOICE.
• Clinical studies of dapivirine gel and ring.
• Drugs with mechanisms other than reverse transcription inhibition, such as entry
inhibitors and integrase inhibitors.
• Combination antiretroviral gel and ring products.
• Continued efficacy end points with gel and ring formulations.
• Development of unique formulations, such as films and tablets.
• Combining HIV protection with contraceptive products.
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Table 1











Frequent application may be required.
Adherence disadvantage.









Can be combined with contraception.
Sustained delivery must occur.
Distribution may not be uniform throughout genital
compartment.
May be uncomfortable or difficult to insert for some.
More complex manufacturing.
Films and tablets Female controlled.
Discrete.
No applicator needed.
Viable option for drugs that would be degraded in aqueous
solution.
Could be formulated for immediate for timed release.
No leakage.
Low side-effect potential.
Can be combined with contraception.
Absorption may be dependent upon local hydration.
Local irritation could result from contact with solids.
Concern for uniformity of distribution.
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Table 2
Human microbicide data for products in development.
Study Product/formulation Methods Efficacy and pharmacokinetic
Tenofovir with or without emtricitabine
Schwartz et al.40 Tenofovir 1% gel. Single and multiple dosing of
once or twice daily 4 ml
applications for 2 weeks in 49
women.
Concentrations ranged from 1.2 × 104 to 9.9 × 106 ng/
ml after a single dose, and 2.1 × 102 to 1.4 × 106 ng/ml
after multiple dosing in fluid samples with no difference
in concentrations between proximal and distal tissues.
Tenofovir diphosphate levels ranged from 7.1 × 103 to
8.8 × 106 ng/ml in endocervical cells, and drug
concentrations were minimal in blood plasma with a
median maximum concentration of 4.0 ng/ml after a




tenofovir oral tablet, or
both.
Crossover design to compare
acceptability, tolerability and
pharmacokinetics in 144
women. Daily doses of either
oral tenofovir, tenofovir gel, or
both, were administered daily
for 6 weeks in each period.
African women preferred the gel form; American
women preferred the oral form; most adverse effects
were associated with oral tenofovir. Tissue
concentrations of the active tenofovir triphosphate were
2352 fmol/mg after gel administration compared with
17 fmol/mg after oral administration. Peripheral blood
mononuclear cell tenofovir–diphosphate concentrations
were 52 fmol/million cells after oral administration and
5 fmol/million cells after gel administration.
Anton et al.43 MTN
006
Tenofovir 1% gel. 18 healthy participants received
a single dose of oral tenofovir,
then a single dose of either
vaginally formulated gel used
rectally or placebo gel rectally
(2:1), followed by 7 days of
daily gel dosing.
Rectal tolerability and acceptability was low after both
single and multiple doses. Ex-vivo human
immunodeficiency virus challenge of rectal biopsies
showed protection after multiple dosing with rectally




Tenofovir 1% gel. 843 women used one
application (4 ml) of gel up to
12 h before and after sex for an
average of 18 months of follow
up.
Tenofovir was 39% effective at preventing HIV
infection with average adherence and 54% effective in
the highest of adherers. The tenofovir concentrations
correlated with likelihood of infection, with women
with cervicovaginal fluid concentrations greater than
1000 ng/ml more likely to be protected and less than
1000 ng/ml less likely to be protected.
VOICE49 Tenofovir 1% gel;
tenofovir 300 mg oral
tablet; tenofovir plus
emtricitabine oral tablet.
Once-daily dosing in 5000
women (approximately 1000
women in the gel arm).
Gel arm stopped early due to futility in November 2011
after 2 years of follow up. Full results expected in early
2013.
FACTS50 Tenofovir 1% gel. Approximately 2200 women
randomly assigned to tenofovir
gel or placebo gel used one
application of gel up to 12 h
before and after sex.
Trial is ongoing.
Dapivirine
Nel et al.55 Dapivirine 0.001%,
0.002%, 0.005%, 0.02%
gel.
2.5 ml applied vaginally twice
daily for 42 days in 119 women.
All doses were found to be safe, with dose proportional
plasma concentrations across the dosing range. The
maximum observed plasma concentration was 474 pg/
ml in the 0.02% dose group.
Nel et al.56 Dapivirine 0.001%,
0.005%, 0.02% gel.
2.5 ml applied vaginally in 18
women for 10 days; once daily
on days 1 and 10 and twice
daily on days 2–9.
All doses were safe and well tolerated. Mean peak
values in cervicovaginal fluid were 4.6–8.3 × 106 pg/ml
on day 1 and 2.3–20.7 × 106 pg/ml on day 10.
Dapivirine concentrations in vaginal tissue biopsies
collected at day 10 were 1.0–356 × 103 pg/mg.
Nel et al.57 Dapivirine 0.05% gel. 2.5 g applied vaginally daily for
11 days in 36 women.
Cervicovaginal fluid concentrations were at least 5 logs
higher than the in-vitro inhibitory concentrations and
maximum plasma concentrations did not exceed 1.1 ng/
ml.
Romano et al.61 Dapivirine 25 mg, and
200 mg ring.
25 women inserted the ring for
7 days, with blood plasma and
vaginal fluid sampling from the
introitus, cervix, and ring area.
Both concentrations of rings were found to have
concentrations throughout the genital tract that
exceeded 1000 times the EC50. The lowest
concentration in any of the tissue samples was over 30-
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Study Product/formulation Methods Efficacy and pharmacokinetic
fold higher than the in-vitro EC90. Mean plasma
concentrations were less than 50 pg/ml.
Nel et al.62 Dapivirine 25 mg Ring. 48 women randomised (3:1) to
dapivirine ring or placebo ring.
Group A inserted a first ring for
28 days then a second ring on
day 31 for another 28 days.
Group B inserted a first ring for
35 days, then a second ring on
day 38 for 21 days, then a third
ring on day 59 for 24 h.
Dapivirine drug concentrations in vaginal fluid peaked
within 24 h remained consistent for up to 35 days at
levels well above the IC50, with even distribution
throughout the genital tract. The maximum plasma
concentration measured was 553 pg/ml.
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